LitAlert ~~ GeneLit.com

    • A novel BRCA2 splice variant identified in a young woman.
    • Nicolussi A, Belardinilli F, Ottini L, Petroni M, Capalbo C, Giannini G, Coppa A.
    • Mol Genet Genomic Med. 2020 Nov 7:e1513. doi: 10.1002/mgg3.1513. Epub ahead of print.
    • Risk of invasive breast cancer in relatives of patients with breast carcinoma in situ: a prospective cohort study.
    • Mukama T, Fallah M, Brenner H, Xu X, Sundquist K, Sundquist J, Kharazmi E.
    • BMC Med. 2020 Nov 5;18(1):295. doi: 10.1186/s12916-020-01772-x.
    • Specialist oncological surgery for removal of the ovaries and fallopian tubes in BRCA1 and BRCA2 pathogenic variant carriers may reduce primary peritoneal cancer risk to very low levels.
    • Crosbie EJ, Flaum N, Harkness EF, Clayton RD, Holland C, Martin-Hirsch P, Wood N, Keating P, Woodward ER, Lalloo F, Donnai P, Edmondson RJ, Evans DG.
    • Int J Cancer. 2020 Nov 5. doi: 10.1002/ijc.33378. Epub ahead of print.
    • Molecular features and functional implications of germline variants in triple-negative breast cancer.
    • Ma D, Chen SY, Ren JX, Pei YC, Jiang CW, Zhao S, Xiao Y, Xu XE, Liu GY, Hu X, Liang XZ, Yu KD, Li DQ, Jiang YZ, Shao ZM.
    • J Natl Cancer Inst. 2020 Nov 5:djaa175. doi: 10.1093/jnci/djaa175. Epub ahead of print.
    • Prognostic and predictive parameters in breast pathology: a pathologist's primer.
    • Allison KH.
    • Mod Pathol. 2020 Nov 5. doi: 10.1038/s41379-020-00704-7. Epub ahead of print.
    • How does genetic testing influence anxiety, depression, and quality of life? A hereditary breast and ovarian cancer syndrome suspects trial.
    • Oliveira FFB, de Barros Silva PG, de Sant'Ana RO, de Albuquerque CGP, Bezerra MJB, Wong DVT, da Silveira Bitencourt F, de Lima Silva-Fernandes IJ, Lima MVA.
    • Support Care Cancer. 2020 Nov 5. doi: 10.1007/s00520-020-05867-2. Epub ahead of print.
    • Clinical impact of BRCA2 mRNA expression in high-grade serous ovarian cancer: validation using the TCGA cohort.
    • Tsibulak I, Wieser V, Welponer H, Leitner K, Hackl H, Marth C, Fiegl H, Zeimet AG.
    • Acta Oncol. 2020 Nov 4:1-4. doi: 10.1080/0284186X.2020.1841288. Epub ahead of print.
    • Pan-cancer landscape of homologous recombination deficiency.
    • Nguyen L, W M Martens J, Van Hoeck A, Cuppen E.
    • Nat Commun. 2020 Nov 4;11(1):5584. doi: 10.1038/s41467-020-19406-4.
    • FDA Approval Summary: Rucaparib for the Treatment of Patients with Deleterious BRCA Mutated -Metastatic Castrate Resistant Prostate Cancer.
    • Anscher MS, Chang E, Gao X, Gong Y, Weinstock C, Bloomquist E, Adeniyi O, Charlab R, Zimmerman S, Serlemitsos-Day M, Ning YM, Mayrosh R, Fuller B, Trentacosti AM, Gallagher P, Bijwaard K, Fahnbulleh F, Diggs F, Arora S, Goldberg KB, Tang S, Amiri-Kordestani L, Pazdur R, Ibrahim A, Beaver JA.
    • Oncologist. 2020 Nov 4. doi: 10.1002/onco.13585. Epub ahead of print.
    • Trends in Positive BRCA Test Results Among Older Women in the United States, 2008-2018.
    • Guo F, Scholl M, Fuchs EL, Wong R, Kuo YF, Berenson AB.
    • JAMA Netw Open. 2020 Nov 2;3(11):e2024358. doi: 10.1001/jamanetworkopen.2020.24358.

    Commentary:

    Time for BRCA Testing Among Women 65 Years or Older in the United States.

    • Cost-Effectiveness of Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer.
    • Wu B, Shi L.
    • J Natl Compr Canc Netw. 2020 Nov 2;18(11):1528-1536. doi: 10.6004/jnccn.2020.7587.